Mizuho Upgrades Atara Biotherapeutics to Outperform, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Outperform, while lowering the price target from $25 to $18.
August 16, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Salim Syed has upgraded Atara Biotherapeutics from Neutral to Outperform, while lowering the price target from $25 to $18.
The upgrade to Outperform suggests a positive outlook on Atara Biotherapeutics' future performance, which is likely to boost investor confidence and drive the stock price up in the short term. However, the lowered price target indicates some caution regarding the company's valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100